As of today, our company Origimm Biotechnology has been acquired by one of the largest pharmaceutical players, Sanofi.
This acquisition will provide Origimm with great opportunities to further expand its research capabilities, continue advancing science and developing highly innovative products for treating various skin diseases and infections associated with the many bacterial species that colonize our skin. The company will continue its operations in Vienna, our team remaining intact and excited about the new challenges ahead!
The Skin Health and Disease: Immune, Epithelial and Microbiome Crosstalk
took place in Hannover / Germany early April this year.
The skin is the largest human organ and the primary interface between the body and the environment. This conference provided a unique setting for in-depth, cross-disciplinary discussions between basic skin scientist and biologists studying immune responses in other barrier organs, as well as dermatologists, cancer biologists, immunologists and many researchers from disparate fields and fostered interaction with industry partners. We could benefit from fruitful discussions on human skin microbiome studies and we could gain insight on the adaptive immune response inside and on the surface of the skin.